Royalty Pharma As of October 10, 2023 ticker dps (an.) 2023 hike 2022 hike 2021 hike
RPRX $0.80 5.3% 11.8% 13.3%
Business yield Hike yrs 5 yr CAGR freq. paid since
Biopharmaceutical Royalties 3.0% 3 N/A Quarter 2020

On January 9, 2023, Royalty Pharma PLC (RPRX) has declared a new quarterly dividend of $0.20 per share, up from $0.19 per share previously. The increased dividend will be paid on March 15, 2023. The next ex-dividend date for RPRX is February 15, 2023. At a stock price of $39.37 the estimated dividend yield is 2%.

Founded in 1996, Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. Royalty Pharma became publicly listed on June 16, 2020.